IPP Bureau

Amydis bags $2.5 million NIH grant to develop first eye test for key ALS biomarker
Amydis bags $2.5 million NIH grant to develop first eye test for key ALS biomarker

By IPP Bureau - March 14, 2026

AI boom, screen overload quietly stealing India’s sleep, new survey warns
AI boom, screen overload quietly stealing India’s sleep, new survey warns

By IPP Bureau - March 14, 2026

MetaVia locks down global patent shield for metabolic drug candidate Vanoglipel
MetaVia locks down global patent shield for metabolic drug candidate Vanoglipel

By IPP Bureau - March 14, 2026

The protections extend through at least 2035, with the potential for further extensions

Citius Oncology reports promising early trial results for therapy for gynecologic cancers
Citius Oncology reports promising early trial results for therapy for gynecologic cancers

By IPP Bureau - March 14, 2026

The Phase 1 dose-escalation trial enrolled 25 evaluable patients and was designed to determine the recommended dose of LYMPHIR

Co-Diagnostics bags key Japanese patent, bolstering global push for rapid PCR testing
Co-Diagnostics bags key Japanese patent, bolstering global push for rapid PCR testing

By IPP Bureau - March 14, 2026

The Japan Patent Office is considered one of the world's most rigorous and meticulous in its review process

WHO Foundation and Novo Nordisk join hands to fight childhood obesity in India
WHO Foundation and Novo Nordisk join hands to fight childhood obesity in India

By IPP Bureau - March 14, 2026

The initiative will focus on creating healthier early-life environments, promoting physical activity, identifying risks early, and strengthening preparedness within primary health care systems

Shilpa Biologicals and mAbTree Biologics secure ODD from USFDA
Shilpa Biologicals and mAbTree Biologics secure ODD from USFDA

By IPP Bureau - March 13, 2026

Marks significant milestone for breakthrough biologic to treat rare blood cancers

Punjab joins hands with Roche to roll out ‘NeuroSakhi’ for women with multiple sclerosis
Punjab joins hands with Roche to roll out ‘NeuroSakhi’ for women with multiple sclerosis

By IPP Bureau - March 12, 2026

The NeuroSakhi initiative aims to close these gaps by strengthening awareness, building patient support networks and improving engagement between healthcare professionals, patients and caregivers across Punjab

Fortis launches 4 specialized clinics in Bengaluru to tackle under-discussed health issues
Fortis launches 4 specialized clinics in Bengaluru to tackle under-discussed health issues

By IPP Bureau - March 12, 2026

The new facilities are designed to provide focused, patient-centric care through advanced diagnostics, minimally invasive treatments, and multidisciplinary expertise

World Glaucoma Week: Experts sound alarm over millions of undiagnosed cases in India
World Glaucoma Week: Experts sound alarm over millions of undiagnosed cases in India

By IPP Bureau - March 12, 2026

Nearly 12 million people are estimated to be living with glaucoma, making the country one of the worst affected globally

BPL Medical Tech acquires South Korea’s Yozma BMtech
BPL Medical Tech acquires South Korea’s Yozma BMtech

By IPP Bureau - March 12, 2026

Launches advanced bone density systems in India & Dubai

India tackles rare diseases head-on at landmark summit in New Delhi
India tackles rare diseases head-on at landmark summit in New Delhi

By IPP Bureau - March 12, 2026

Industry leaders highlighted the pharmaceutical sector’s role in advancing research, innovation, early screening, and multi-stakeholder collaboration

Agilent to acquire Biocare Medical for $950M, supercharging cancer diagnostics portfolio
Agilent to acquire Biocare Medical for $950M, supercharging cancer diagnostics portfolio

By IPP Bureau - March 12, 2026

The acquisition of Biocare enhances Agilent’s pathology portfolio and reflects our strategy to drive long-term growth

NewcelX and Eledon join forces to advance potential Type 1 diabetes cure
NewcelX and Eledon join forces to advance potential Type 1 diabetes cure

By IPP Bureau - March 12, 2026

The collaboration will leverage this clinical experience to inform NCEL-101 development, streamline regulatory pathways, and potentially accelerate timelines for achieving durable graft survival comparable to donor human islets

FDA nod to LifeVac De Novo, paving for next-generation anti-choking device
FDA nod to LifeVac De Novo, paving for next-generation anti-choking device

By IPP Bureau - March 12, 2026

The FDA classified LifeVac as a Class II medical device

Latest Stories

Interviews

Packaging